News | July 19, 2024
Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.9 million SEK
Find out more
News (2)
Devyser announces expanded commercial agreement with Thermo Fisher Scientific for post-transplant monitoring NGS products
Devyser launches updated Y-Chromosomal microdeletion test
Devyser wins all-time high tender for up to 75 MSEK
Devyser wins tender for oncology NGS solutions in Italy
Devyser wins tender for thalassemia in Italy
Devyser Diagnostics AB publishes quarterly report for the period January to March 2024
Devyser receives IVDR approval for post-transplant monitoring software
Devyser partners with Hamilton to automate laboratory NGS workflows
Devyser receives MDSAP certification for Brazil
Devyser publishes annual report for 2023
Devyser´s annual report 2023 has today been published on the company´s website. The report is...
Devyser achieves breakthrough in the US with cystic fibrosis NGS test
Devyser has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is...